Olema Q2 2026: Cash Runway Extended to Mid-2028, OPERA-01 Top-Line Data Expected Q1 2027
OLMA has more than doubled off its 52-week low of $4.47.
Summary
Olema Pharmaceuticals reported Q2 2026 financials with $461.1M in cash, extending runway to mid-2028. Key clinical milestones include completed enrollment in the pivotal OPERA-01 trial with top-line data expected Q1 2027, and initial Phase 1 data for OP-3136.
Key Events · Earnings and Guidance · OLMA
-
Cash Runway Extended to Mid-2028
Cash, cash equivalents, and marketable securities totaled $461.1 million as of June 30, 2026, funding operations into mid-2028. The prior quarter's going concern warning is not repeated.
-
OPERA-01 Enrollment Complete, Top-Line Data Q1 2027
The pivotal Phase 3 monotherapy trial of palazestrant in ER+/HER2- metastatic breast cancer has completed enrollment, with top-line results expected in Q1 2027 and potential NDA submission in 2027.
-
OP-3136 Phase 1 Data Presented, Bayer Collaboration Initiated
Initial clinical data for the KAT6 inhibitor OP-3136 showed tolerability and anti-tumor activity. A new clinical trial collaboration with Bayer will evaluate OP-3136 in combination with NUBEQA in prostate cancer.
-
Net Loss Widens on Increased R&D Investment
Net loss for Q2 2026 was $63.2 million, up from $43.8 million in Q2 2025, driven by a 32% increase in R&D expenses to $57.8 million, reflecting expanded clinical trial activity.
Analysis · OLMA · Life Sciences
A strengthened balance sheet headlines Olema's Q2 2026 report, with $461.1 million in cash and equivalents extending the runway to mid-2028. The lead candidate, palazestrant, is advancing through pivotal Phase 3 trials: enrollment in OPERA-01 is complete, and top-line results are anticipated in Q1 2027. Progress with OP-3136 also stands out, including initial Phase 1 data and a newly initiated Bayer collaboration. While operating losses widened, the increased spending reflects investment in late-stage development, and the ATM offering provided additional capital. Notably, the going concern warning from the prior quarter is absent, and management now expresses confidence in funding operations for at least 12 months.
At the time of this filing, OLMA was trading at $11.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $4.47 to $36.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.